After a new approval & multi-million dollar deals, are ADCs finally moving to the forefront in the targeted therapy space? Read more from @BeaconIntel: https://t.co/jwjCzFPXK6 #ADC#OncologyNews
For readers interested in the R&D landscape for antibody-drug conjugates such as the one involved in AstraZeneca's multi-billion dollar collaboration with Daiichi Sankyo, here's a recent review https://t.co/GT34IyDXnB
Correctly/natively re-bridging your disulfide bonds when you conjugate to an antibody matters!! - Check out our investigation led by Calise Bahou in collaboration with @lifearc1 - https://t.co/DS3TMUO9tM @UCLChemistry@BioconjChem
Our work on highly-loaded hydrophilic antibody-drug conjugates (#ADCs) is out in @ChemicalScience 👍 Thanks to all co-authors and institutions! @PapotSebastien @ICBMSLyon@crcl @canceroCLARA @Pulsalys https://t.co/lkaEsh5IXt